Educational experience:

(1) From October 1987 to June 1993, Pennsylvania Medical College, Ph.D. in Pharmacology.

(2) From September 1987 to June 1992, Third Military Medical University, Doctor of Trauma Surgery.

(3) From September 1983 to June 1986, Third Military Medical University, Master of Pathophysiology.

(4) From September 1978 to June 1983, Wenzhou Medical College, Bachelor of Clinical Medicine. 

Work experience: 

Postdoctoral work experience:

(1) From September 1994 to September 1996, Harvard Medical School (Department of Neurology, Massachusetts General Hospital). 

Scientific research and academic work experience (except postdoctoral work experience):

(1) From January 2016 to present, Professor, Affiliated Ophthalmology Hospital, Wenzhou Medical University.

(2) From February 2010 to December 2015, Professor, Department of Neurology, Medical College, Boston University, USA.

(3) From June 2001 to January 2010, Associate Professor, Department of Neurology, Medical College, Boston University, USA.

(4) From October 1996 to June 2001, lecturer, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, USA

● Committed to the molecular pharmacology of adenosine receptors for more than 26 years;

● Multiple key and important contributions in establishing A_2A receptor as a non-dopaminergic target for treating Parkinson's disease;

● Participating in the development of clinical drugs for A_2A receptor antagonists for Parkinson's disease for 20 years as a scientific consultant, which was approved by the US FDA in September 2019;

● Publishing more than 250 papers in Nature Medicine, PNAS, Molecular Psychology and other publications, which have been cited more than 21000 times, with an H factor of 81.

1. Research direction 1: the structural basis of the integration of visual function and brain function

2. Research direction 2: Molecular and loop mechanisms of light-controlled visual development and brain function.

3. Research direction 3: Early diagnosis and treatment of neuropsychiatric diseases targeting retina.

Our team is dedicated to researching the neurobiology and molecular pharmacology of adenosine receptors, with a particular focus on the adenosine A_2A receptor in the field of neuropsychiatric diseases. Our research has advanced the use of adenosine A_2A receptor antagonists as a novel therapeutic strategy for neurodegenerative disorders like Parkinson's disease, while also deepening our understanding of the biological function of adenosine receptors in the pathological processes underlying neuropsychiatric conditions. Professor Jiangfan Chen, as a scientific consultant, has been involved in the development of clinical drugs targeting A_2A receptor antagonists for Parkinson's disease for over 20 years, leading to FDA approval in September 2019.

Since 2020, supported by the State Key Laboratory of Optometrics and Visual Sciences, Wenzhou Medical University's "Eye-brain Research Center" has been established by integrating research findings from this laboratory and leveraging disciplinary expertise from the Key Laboratory of Optometrics and Visual Sciences. The center aims to establish a comprehensive understanding of retinal-brain connectivity at a cellular level throughout the entire brain. Additionally, it seeks to explore the significance of eye-brain connections pathways in visual neurobiology, particularly investigating potential treatments for visual developmental disorders (such as amblyopia) and neuropsychiatric diseases (such as depression and PD) through light stimulation along these pathways.